People
Our Team
We are a multidisciplinary team with expertise in biopharmaceuticals, neurosciences, ophthalmology, and health technologies, driven to bring a new perspective to the world of eye care.
We have built Dopavision to develop breakthrough healthcare solutions that are accessible and designed for everyday life. Our team combines scientific and technical curiosity with the goal of empowering as many people as possible to build a healthier, brighter future. Our office is located in the heart of Berlin.
FOUNDING AND Management Team
Dr. Hamed Bahmani
Founder
Hamed is the founder of Dopavision. He combines expertise in neuroscience, vision sciences, and engineering with an innovative mindset that drives Dopavision. He has years of experience in academia and industry, and is currently a visiting scholar at the Max Planck Institute for Biological Cybernetics.
Dr. Mark Wuttke
Chief Executive Officer
Mark is dedicated to addressing unmet needs for patients through novel solutions. He brings more than two decades of healthcare business expertise, including experience in the development and commercialization of ophthalmology products at Novartis, a global leader in eye health. He has also worked in equity research at Credit Suisse, management consulting at Booz & Co. and healthcare consulting at Asten BioPharma Advisors, which he co-founded.
Dr. Andreas Balser
Chief Technology Officer
Andreas is the Chief Technology Officer of Dopavision. He is passionate to merge his experience from product management, software and technology management as well as strategy consulting to make our vision become reality. His healthcare industry experience allows him to ensure Dopavision’s product and processes adhere to the highest regulatory standards. He has previously worked with Meierhofer AG and McKinsey&Company, among others.
Dr. Gabriela Burian
Chief Medical Officer
Gabriela is a trained physician and epidemiologist. She is passionate about turning innovative ideas into new medical therapies that have practical applications for many patients by combining medical science and scientific methodology to achieve improved patient clinical care. She has expertise in biomedical and clinical research of new therapies in the field of ophthalmology, retina, which she acquired in academia, the pharmaceutical and biotechnology industry, and as an independent medical strategy advisor.
Dr. Jens Ellrich
Chief Scientific Officer
Jens is an expert in translational medicine with a strong background and a track record in basic and clinical neurosciences, including various eye diseases. He brings a wealth of scientific knowledge and considerable experience in the development of digital therapeutics. An Adjunct Professor of Neuroscience at the Medical Faculty of the University of Erlangen-Nuremberg, Jens has authorship on more than 85 peer-reviewed papers and serves on the Editorial Boards of two scientific journals.
Advisory board members and observers
Dr. Dirk Sauer
Board Chair
Dopavision
Dr. Annegret de Baey-Diepolder
Venture Partner
Seventure Partners
Dr. Oliver Reuß
Executive Director, Investment Manager
Boehringer Ingelheim Venture Fund
Brooke Paige
Global Alliance Management Lead, Neuroscience and Digital
Novartis
Christian Lautner
Co-Founder
Ababax.Health
Stefan Zundel
Co-Founder
Dopavision
Investors
Seventure Partners
Novartis
Boehringer Ingelheim Venture Fund
Ababax.Health
Career
Does Dopavision sound exciting to you? We are looking for talented people to join our team and help us bring our vision to life.
Does your profile not match? Nevertheless, does Dopavision sound exciting to you?
If so, please reach out to us with your profile at jobs@dopavision.com
Our Partners
Dopavision is funded as part of the BMBF’s Industry-in-Clinic Platform Program (FKZ: 13GW0625)